Genmab — December 2016
-
@Bibob, hvor ser du den analyse fra Google Finance henne ?
-
-
Som jeg ser det, er geopolitiske hændelser og sektorrotation væk fra biotek (og dermed generel justering ned af aktierne pris i denne gruppe) den største risiko for Genmab aktiens pris på den korte bane. Alt andet lige ligger risikoen opad som jeg ser det.
-
-
Det her danner præcedens for en meget hurtig udrulning i anden linje, og hurtigt voksende salgstal fra måned til måned, som støt vil løfte kursen.http://s21.q4cdn.com/406493826/files/doc_news/Diplomat-to-Dispense-Multiple-Myeloma-Combination-Drug-DARZALEX.pdf
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind
Twitter: Rachel Gravesen @RachelGravesen